Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibi
文献类型：期刊论文
| 作者 | Qiang Wang1,5; Feiyang Liu4,5 ; Qi S(亓爽)1,5; Ziping Qi1,5; Beilei Wang4,5; Aoli Wang4,5; Zongru Jiang4,5; Wenchao Wang1,5; Qingsong Liu1,2,3,4,5; Jing Liu1,3,5
|
| 刊名 | Eur. J. Med. Chem.
 |
| 出版日期 | 2018-03 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/42690]  |
| 专题 | 医学_专题未命名 |
| 通讯作者 | Qingsong Liu; Jing Liu |
| 作者单位 | 1.CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui, 230031, PR China 2.Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230088, PR China 3.Hefei Science Center, Chinese Academy of Sciences, 350 Shushanhu Road, Hefei, 230031, Anhui, PR China 4.University of Science and Technology of China, Hefei, Anhui, 230036, PR China 5.High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui, 230031, PR China |
| 推荐引用方式 GB/T 7714 | Qiang Wang,Feiyang Liu,Qi S,et al. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibi[J]. Eur. J. Med. Chem.,2018. |
| APA | Qiang Wang.,Feiyang Liu.,Qi S.,Ziping Qi.,Beilei Wang.,...&Jing Liu.(2018).Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibi.Eur. J. Med. Chem.. |
| MLA | Qiang Wang,et al."Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibi".Eur. J. Med. Chem. (2018). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。